Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
aciclovir
- Development stage
- Approved
- Lead developer
- GSK
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Administration
- Oral, Intravenous, Topical, Ophthalmic, Buccal
01
Overview
Aciclovir (also known as acyclovir) is an antiviral medication primarily used to treat infections caused by herpes viruses, including herpes simplex virus (HSV) and varicella zoster virus (VZV). It is indicated for the treatment of genital herpes (both initial and recurrent episodes), cold sores (herpes labialis), shingles (herpes zoster), chickenpox (varicella), neonatal herpes simplex infection, and herpes simplex encephalitis. Aciclovir may also be used prophylactically in immunocompromised patients to prevent HSV or VZV reactivation. The drug acts as a synthetic nucleoside analogue that inhibits viral DNA polymerase after being phosphorylated by viral thymidine kinase. This action blocks viral DNA replication without affecting normal cellular processes[1][2][5][7]. Aciclovir was originally developed by GlaxoSmithKline.
- Brand names
- ZoviraxSitavigAvaclyrZovirax CreamZovirax Ointment
- Other names
- acyclovir
02
Targets
Herpesvirus DNA polymeraseDNA polymerase family
Beyond the preview
Go deeper on aciclovir.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on aciclovir.